%PDF-1.4
%
96 0 obj
<>
endobj
93 0 obj
<>
endobj
186 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-06-08T13:14:52Z
2024-03-28T13:07:46-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T13:07:46-07:00
application/pdf
Heather
2003-279.july
uuid:af120950-1dd1-11b2-0a00-a208275d6100
uuid:af120952-1dd1-11b2-0a00-aa0000000000
endstream
endobj
80 0 obj
<>
endobj
82 0 obj
<>
endobj
81 0 obj
<>
endobj
83 0 obj
<>
endobj
48 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 74 0 R/Type/Page>>
endobj
187 0 obj
[192 0 R]
endobj
188 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 10 0 0 10 54 713.1616 Tm
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 61 703.1616 Tm
[(1.)-875.1 (W)79.9 (ood J. Osteoarthritis and its management. Pharm )]TJ
0 Tc 1.675 -1.25 Td
(J 1999;262:744\3206.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (Murray CJL, Lopez )54.8 (AD. )17.7 (The global burden of disease. Geneva:)]TJ
1.675 -1.25 Td
[(W)79.9 (orld Health Or)17.7 (ganization; 1997.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Boh LE. Osteoarthritis. In: DiPiro JT)73.9 (, )17.7 (T)69.9 (albert RL, Hayes PE, et al,)]TJ
1.675 -1.25 Td
[(editors. Pharmacotherapy)64.8 (. )54.8 (A)-220.1 (pathophysiologic approach. 2nd ed.)]TJ
0 Tc 0 -1.25 TD
[(Norwalk, CT)49.8 (: )54.8 (Appleton and Lange; 1993:1330\32042.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Pendleton )54.8 (A, )54.8 (Arden N, Dougados M, et al. EULAR )]TJ
1.675 -1.25 Td
(recommendations for the management of knee osteoarthritis:)Tj
T*
[(Report of a )17.7 (T)69.9 (ask Force of the Standing Committee for International)]TJ
T*
[(Clinical Studies Including )17.7 (Therapeutic )17.7 (T)35 (rials \(ESCISIT\). )54.8 (Ann)]TJ
0 Tc T*
(Rheum Dis 2000;59:936\32044.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Osteoarthritis and its treatment. Merec Bulletin 1994;5:13\3206.)]TJ
T*
[(6.)-875.1 (Cicuttini F)79.7 (, Spector )17.7 (TD. Osteoarthritis. Medicine 1998;26:68\32071.)]TJ
T*
[(7.)-875.1 (W)79.9 (alker)19.7 (-Bone K, Javaid K, )54.8 (Arden N, Cooper C. Regular review:)]TJ
1.675 -1.25 Td
(medical management of osteoarthritis. BMJ 2000;321:936\32040.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Brandt KD. Osteoarthritis. In: Braunwald E, Fauci )54.8 (AS, Kasper DL,)]TJ
1.675 -1.25 Td
[(et al, editors. Harrison\325)54.8 (s principles of internal medicine. 15th ed.)]TJ
T*
[(New )36.8 (Y)99.8 (ork: McGraw-Hill; 2001.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (American College of Rheumatology Subcommittee on)]TJ
1.675 -1.25 Td
(Osteoarthritis Guidelines. Special article. Recommendations for the)Tj
T*
[(medical management of osteoarthritis of the hip and knee. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2000;43:1905\32015.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Hogue J, Mersfelder )17.7 (TL. Pathophysiology and first-line treatment)]TJ
2.175 -1.25 Td
[(of osteoarthritis. )54.8 (Ann Pharmacother 2002;36:679\32086.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Henry D, Lim LL-Y)128.8 (, Rodriguez LAG, et al. )17.7 (V)110.8 (ariability in risk of)]TJ
2.1381 -1.25 Td
(gastrointestinal complications with individual non-steroidal )Tj
T*
(anti-inflammatory drugs: results of a collaborative meta-analysis.)Tj
0 Tc T*
(BMJ 1996;312:1563\3206.)Tj
-0.00011 Tc 30.825 36.421 Td
[(12.)-875.1 (DeArmond B, Francisco CA, Lin J-S, et al. Safety profile of )]TJ
2.175 -1.25 Td
[(over)19.7 (-the-counter naproxen sodium. Clin )17.7 (Ther 1995;17:587\320601.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Bansal )17.7 (V)128.9 (,)-0.1 ( Dex )17.7 (T)74 (, Proskin H, Garref)17.7 (fa S. )54.8 (A)-220.1 (look at the safety profile)]TJ
2.175 -1.25 Td
[(of over)19.7 (-the-counter naproxen sodium: a meta-analysis. J Clin)]TJ
T*
(Pharmacol 2001;41:127\32038.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Doyle G, Furey S, Berlin R, et al. Gastrointestinal safety and )]TJ
2.175 -1.25 Td
[(tolerance of ibuprofen at maximum over)19.7 (-the-counter dose. )54.8 (Aliment)]TJ
0 Tc 0.0072 Tw T*
[(Pharmacol Ther )-17.8 (1999;13:897\320906.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Kiersch )17.7 (T)79.9 (A, Halladay SC, Koschik M. )54.8 (A)-220.1 (double-blind, randomized)]TJ
2.175 -1.25 Td
(study of naproxen sodium, ibuprofen, and placebo in postoperative)Tj
T*
[(dental pain. Clin )17.7 (Ther 1993;15:845\32054.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Kiersch )17.7 (T)79.9 (A, Halladay SC, Hormel PC. )54.8 (A)-220.1 (single-dose double-blind)]TJ
2.175 -1.25 Td
(comparison of naproxen sodium, acetaminophen, and placebo in)Tj
T*
[(postoperative dental pain. Clin )17.7 (Ther 1994;16:394\320404.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Milsom I, Minic M, Dawood MY)128.8 (, et al. Comparison of the ef)17.7 (ficacy)]TJ
2.175 -1.25 Td
(and safety of nonprescription doses of naproxen and naproxen)Tj
T*
(sodium with ibuprofen, acetaminophen, and placebo in the )Tj
T*
(treatment of primary dysmenorrhea: a pooled analysis of five)Tj
0 Tc T*
[(studies. Clin )17.7 (Ther 2002;24:1384\320400.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875.1 (Fricke JR, Halladay SC, Francisco CA. Ef)17.7 (ficacy and safety of)]TJ
2.175 -1.25 Td
[(naproxen sodium and ibuprofen for pain relief after oral sur)17.7 (gery)64.8 (.)]TJ
0 Tc T*
[(Curr )17.8 (Ther Res 1993;54:619\32027.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (W)79.9 (atson MC, Brookes ST)73.9 (, Kirwan JR, Faulkner )54.8 (A. Non-aspirin,)]TJ
2.175 -1.25 Td
(non-steroidal anti-inflammatory drugs for osteoarthritis of the knee.)Tj
T*
(Cochrane Database Syst Rev 2000;2:CD000142.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Sinclair HK, Bond CM, Hannaford PC. Long term follow-up)]TJ
2.175 -1.25 Td
(studies of users of non-prescription medicines purchased from)Tj
T*
(community pharmacies: some methodological issues. Drug Safety)Tj
0 Tc 0 Tw T*
(2001;24:929-38.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Schiff and Minic: )17.7 (Analgesics in OA)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1383)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
74 0 obj
<>stream
8;Z\7$a.B$#ikn#j>p(O!':WaRr$P14ZmG4dDCG_)PqON[Kf^a8F,Wb/XXo@i#[BT_<$(`@MVc7%kY/-6\'"
gJB'5j(\3t]HFbUhXg!g<5%oo7A@7YHghu"d6']\@4]?E453K2Z.!AD`7_mZ?EAK'
AKPa!VHr`YqeU`'*g/R1KPm.1/'AEC534Y.0$hHSC4]/KO$s:Y^,V_#%AK).Op_:Q
n>HC[U9ma(_OhdNVcGo#(*P3NU.om[Y^n]%$pEX/(Y#@;_Dk3!&J'bAgS`[,E7$+h
Kd;`NW_b)X$ACg?:ad"bhhJ5m/OjV/^,*@q>J#4W'9)nkrWW@fS!b#~>
endstream
endobj
78 0 obj
[/Indexed/DeviceRGB 255 77 0 R]
endobj
77 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
163 0 obj
<>
endobj
51 0 obj
<>
endobj
103 0 obj
<>
endobj
99 0 obj
<>
endobj
140 0 obj
<>
endobj
191 0 obj
<>
endobj
100 0 obj
<>
endobj
133 0 obj
<>stream
HUiPSYC!=5˔-"2:-""",@%l@ @dlp]DDefl/S3ў?Snթ[wϩ{{.Ʋ`a3`HA_b8>UwYdxBK86EKg6?[ؿ++A+8 ouw"0l8qg_0C%HNOZ~5q$L&'
2Yb~7M":/g嘫oLDt<-ΊOg`AP,[,Z`扲D$A|//cdl-XYز|جͮ,X8`R=Xem1o3-,W .{*6A^ycOL&ھ4,-hggt9 }w4.ꡳaʅ]w]kKshi_,O>zK+FZe)UrIaI^zR\/M
dYJrh Xb AtB;!͡g'3!J6z1[/fg=8k{
W'p8hrSc+K@Ιȫe8cy!퍎c}}d_.5v
k~ɨyό>-SDf.*25lK|TLX q3Th(jN2HUC]r$+:uͱz;O^}'/jdFDu+-YI5>c-o:oMG!:"Ɗ#+:3em哕9D